RxDoctor Payments DataLook up a doctor →

Greg Eudy, MD

Rheumatology · Birmingham, ALNPI 1154426872

Payments from drug & device makers

$32,904in general payments, 2019–2025

Across 1,643 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$6K
  • Amgen$5K
  • Pfizer$3K
  • UCB, Inc.$3K
  • Johnson & Johnson$2K
  • Novartis$2K
  • plus $12K from 43 others

What the payments were for

  • Consulting fees$4001%
  • Food & beverage$32,22798%
  • Education$2771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,904 in reported general payments places this provider in the 75th percentile of 90 rheumatology providers in Alabama.

See all rheumatology providers in Alabama

Medicare billing

Part B allowed, 2024
$5,386,757
Medicare patients
659
Services billed
315,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StrensiqAsfotase Alfa22$937,889
RinvoqUpadacitinib109$678,868
Enbrel SureclickEtanercept76$677,232
Humira(Cf) PenAdalimumab86$597,936
StelaraUstekinumab12$338,151
ArcalystRilonacept15$334,665
TymlosAbaloparatide99$266,854
Xeljanz XrTofacitinib Citrate43$240,468
Orencia ClickjectAbatacept43$236,113
Cimzia (2 Pack)Certolizumab Pegol31$174,995
EnbrelEtanercept15$140,787
Hydroxychloroquine Sulfate1,729$133,794
XeljanzTofacitinib Citrate22$128,012
Cosentyx Unoready PenSecukinumab14$100,832
OrenciaAbatacept/Maltose21$100,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaStrensiq$1,833$937,88922 claims
AbbVieRinvoq, Humira$6,245$755,626120 claims
Johnson & JohnsonStelara, Simponi, Remicade$2,120$499,61540 claims
Radius Health, Inc.Tymlos$742$266,85499 claims
AmgenEnbrel, Rayos$4,946$200,77130 claims
UCB, Inc.Cimzia (2 Pack)$2,598$174,99531 claims
E.r. Squibb & Sons, L.L.C.Orencia, Orencia$1,754$166,67333 claims
PfizerXeljanz$3,022$128,01222 claims
SanofiKevzara$203$94,75022 claims
Collegium Pharmaceutical, Inc.Nucynta Er, Nucynta$11$70,16055 claims
GSKBenlysta$1,125$60,13012 claims
Lilly USA, LLCOlumiant$698$59,13722 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 90 rheumatology providers in Alabama.

Other rheumatology in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →